Cocrystal Pharma (COCP) Net Cash Flow (2010 - 2026)

Cocrystal Pharma (COCP) has 16 years of Net Cash Flow data on file, last reported at -$2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 20.38% year-over-year to -$2.3 million; the trailing twelve-month figure through Mar 2026 stood at -$6.6 million (up 55.97% YoY), and the FY2025 full-year result was -$2.8 million, up 82.76% from the prior year.
• Net Cash Flow eased to -$2.3 million in Q1 2026, from -$712000.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of -$712000.0 in Q4 2025 to a low of -$8.9 million in Q3 2022.
• A 5-year average of -$3.4 million and a median of -$3.2 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 1561.19% in 2022 and jumped 77.47% in 2025, its largest moves.
• Tracing COCP's Net Cash Flow over 5 years: stood at -$4.9 million in 2022, then jumped by 31.09% to -$3.4 million in 2023, then rose by 6.65% to -$3.2 million in 2024, then jumped by 77.47% to -$712000.0 in 2025, then slumped by 228.65% to -$2.3 million in 2026.
• Business Quant data shows COCP's Net Cash Flow at -$2.3 million in Q1 2026, -$712000.0 in Q4 2025, and -$1.4 million in Q3 2025.